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Abstract
Background: The aim of this longitudinal study was to assess with positron emission tomography (PET) the
relationship between levels of inflammation and the loads of aggregated β-amyloid and tau at baseline and again
after 2 years in prodromal Alzheimer's disease.
Methods: Forty-three subjects with mild cognitive impairment (MCI) had serial 11C-PK11195 PET over 2 years to
measure inflammation changes, and 11C-PiB PET to determine β-amyloid fibril load; 22 also had serial 18F-
Flortaucipir PET to determine tau tangle load. Cortical surface statistical mapping was used to localise areas
showing significant changes in tracer binding over time and to interrogate correlations between tracer binding of
the tracers at baseline and after 2 years.
Results: Those MCI subjects with high 11C-PiB uptake at baseline (classified as prodromal Alzheimer’s disease) had
raised inflammation levels which significantly declined across cortical regions over 2 years although their β-amyloid
levels continued to rise. Those MCI cases who had low/normal 11C-PiB uptake at baseline but their levels then rose
over 2 years were classified as prodromal AD with low Thal phase 1-2 amyloid deposition at baseline. They showed
levels of cortical inflammation which correlated with their rising β-amyloid load. Those MCI cases with baseline low
11C-PiB uptake that remained stable were classified as non-AD, and they showed no correlated inflammation levels.
Finally, MCI cases which showed both high 11C-PiB and 18F-Flortaucipir uptake at baseline (MCI due to AD) showed
a further rise in their tau tangle load over 2 years with a correlated rise in levels of inflammation.
Conclusions: Our baseline and 2-year imaging findings are compatible with a biphasic trajectory of inflammation
in Alzheimer’s disease: MCI cases with low baseline but subsequently rising β-amyloid load show correlated levels
of microglial activation which then later decline when the β-amyloid load approaches AD levels. Later, as tau
tangles form in β-amyloid positive MCI cases with prodromal AD, the rising tau load is associated with higher levels
of inflammation.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized clinically by progressive impairment of
cognitive functions and, in particular, early involvement
of short-term memory. The pathological hallmarks of
AD are the presence of extracellular beta-amyloid (Aβ)
fibrillar plaques and intraneuronal neurofibrillary tau
tangles (NFT). Brain slices of AD cases show that both
extracellular Aβ plaques and neurons containing NFTs
are surrounded by activated microglia, the intrinsic cel-
lular immune inflammatory response to brain injury [1,
2]. The role and the trajectory of this inflammation are
still being debated [3]. Activated microglia can exhibit a
protective or neurotoxic phenotype depending on their
environment. The protective phenotype is phagic, clear-
ing Aβ fibrils and neuronal debris, remodelling synapses
and releasing growth factors. In contrast, the neurotoxic
phenotype releases cytokines such as TNFα and IL1β
which can cause or contribute to tissue damage and dis-
ease pathology so driving disease progression [4].
It is thought that Aβ aggregation begins in a preclin-
ical phase of Alzheimer’s disease and rises over a decade,
approaching a plateau in the late prodromal phase when
mild cognitive impairment (MCI) is present [5, 6].
Hyperphosphorylation of tau and its aggregation to form
NFTs begins during the prodromal phase of AD causing
neuronal dysfunction, cognitive decline and progression
to clinical dementia [7].
The amyloid cascade hypothesis [8] posits tau path-
ology that occurs downstream from the deposition of Aβ
plaques. PET studies report that cortical tau tangles are
only detected when Aβ deposition is already present [9].
The link between Aβ and tau aggregation may involve
activation of microglia. Soluble Aβ oligomers have
been reported to activate microglial cells in a cell cul-
ture study [10]. Transgenic Alzheimer mouse studies
have shown that activation of microglia precedes tau
aggregation [11] and promotes tau hyperphosphoryla-
tion via cytokine release with subsequent formation of
NFTs [12].
It has been suggested that brain inflammation initially
occurs as a protective response against dementia, the
microglia phagocytosing Aβ fibrils, but this fails, and the
microglial activity declines. Later, as tau tangles accumu-
late, a second phase of increasing microglial activation
occurs which is neurotoxic and this phenotype drives
disease progression [3, 13, 14].
PET imaging biomarkers to detect Aβ-fibrils, tau-
tangles and the translocator protein (TSPO) expressed
by activated microglia have made it possible to examine
in vivo the longitudinal time course of the inter-
relationships between Aβ and P-tau aggregation and the
associated neuroinflammation. Using PET to serially
map the relative spatial and temporal distributions of
Aβ, tau and inflammation in prodromal Alzheimer’s dis-
ease should further our understanding of the roles of in-
flammation in driving or protecting against Alzheimer’s
disease progression.
We previously reported that at baseline 60% of our
MCI subjects showed a raised brain Aβ load, and thus
represented prodromal Alzheimer’s disease (pAD)
cases—80 % of these pAD subjects also showed clusters
of brain inflammation [15]. A correlation between cor-
tical Aβ load and levels of microglial activation could be
detected in a number of these clusters. This cross-
sectional baseline study found no significant association
between tau tangle load and inflammation levels in early
MCI [16]. Here, we report inflammation levels 2 years
later in our MCI cohort and their relationship with Aβ
plaque and tau tangle loads.
Using PiB, flortaucipir and PK11195 PET imaging, our
objectives were to:
1. Determine the longitudinal changes over 2 years in
levels of fibrillar β-amyloid, tau tangles and inflam-
mation (activated microglia) in mild cognitive im-
pairment (MCI) cases.
2. Investigate the association between levels of fibrillar
β-amyloid and inflammation in MCI cases who
have a low/normal PiB PET signal at baseline but
which subsequently rises as β-amyloid fibrils are de-
posited over the next 2 years. These cases are con-
sidered to have early prodromal Alzheimer’s disease
(AD) with Thal phase 1-2 amyloid pathology missed
by amyloid PET when applying a conventional PiB
threshold for abnormality and are tau negative.
3. Examine the associations between levels of
inflammation, β-amyloid load and tau tangle load in
MCI cases who have a high β-amyloid signal ap-
proaching Alzheimer levels at baseline. These sub-
jects have prodromal AD, and a majority show a
rise in tau levels over 2 years.
We hypothesised that:
(a) Inflammation levels in MCI cases with a high β-
amyloid load will decrease over 2 years as the acti-
vated microglia fail to clear amyloid and tau.
(b) The subgroup of MCI cases with low β-amyloid at
baseline which then becomes elevated will show in-
flammation levels that rise alongside their increas-
ing β-amyloid load over 2 years.
(c) MCI cases with a β-amyloid load approaching
Alzheimer levels at baseline will show an increas-
ing tau tangle load over 2 years. These cases will
also show rising inflammation levels but these
correlate with tau tangle rather than their β-
amyloid load.
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Methods
Study population
Participants were recruited from Memory/Dementia clinics
in Denmark or by advertisement and were screened/
assessed as previously described [15]. Our Alzheimer’s dis-
ease cases were formally diagnosed by these clinics in
Denmark in accordance with the ICD-10 clinical criteria
while the MCI subjects fulfilled the Petersen clinical criteria
[17]—we applied no formal diagnostic rating threshold for
the severity of their cognitive deficits. During the recruiting
period, we ascertained a total number of 43 MCI subjects.
The programme was initially designed to longitudinally in-
vestigate the inter-relationship between Aβ fibril load and
levels of inflammation in MCI subjects. During the conduct
of the study, 18F-Flortaucipir PET also became available to
image tau tangles. The PET scans were scheduled to all be
performed within 10weeks, but for six subjects, the flortau-
cipir scan was performed up to 1 year later than the two
other scans due to delayed tracer availability (see Additional
file 1).
Cognitive assessment
All subjects were cognitively rated by trained research
assistants under the supervision of an experienced
psychologist. Cognitive status was rated with the Mon-
treal Cognitive Assessment (MoCA). We performed no
inter- or extrapolation for missing data. To protect
against bias, our cognitive assessments were performed
by raters blinded to all other aspects of the subject’s
condition and scan findings.
Image processing
MRIs were acquired with a Skyra 3 Tesla system (Siemens,
Erlangen, Germany), and PET scans were acquired with a
high resolution research tomograph (ECAT HRRT; CTI/
Siemens, Knoxwille, TN, USA)—both according to pre-
viously described protocols [15]. Target doses of 400MBq
11C-PiB, 11C-PK11195 and 370MBq 18F-Flortaucipir were
intravenously administered as boluses followed by a 10-ml
saline flush. PiB PET was acquired for 50min 40–90min
post injection. Flortaucipir PET was acquired for 40min
80–120min post injection. The 60-min 11C-PK11195 emis-
sion PET scans were initiated with a 30-s ‘background’
frame prior to tracer injection. The dynamic scan was ac-
quired in list mode, and data were re-binned as 1 × 30 s, 6
× 10 s, 2 × 30 s, 2 × 60 s, 3 × 120 s, and 10 × 300 s ‘back-
ground’ time frames.
The MINC software (http://en.wikibooks.org/wiki/
MINC) [18] was used to segment MRI volumes into im-
ages of grey (GM) and white (WM) matter and cerebro-
spinal fluid (CSF) [19] and to spatially normalise the
MRI and PET images into MNI space [20]. GM masks
were convolved with a probabilistic atlas [21] to define
regions of interest (ROIs) on the individual’s GM
template.
The spatially normalised PiB and flortaucipir images
were summed from 60–90 to 80–100min, respectively,
and voxel signals were divided by the mean signal from
the individual’s cerebellar GM to generate PiB and flor-
taucipir standardised uptake value ratio (SUVR) images.
Cases were categorised as high or low Aβ load based on
the bimodal distribution of group baseline data—there
was a clear separation between raised and normal PiB
MCI ranges above and below a composite cortical:cere-
bellar PiB SUVR of 1.5 [15]. The composite cortical PiB
uptake was defined as the volume weighted average of
temporal, parietal and frontal GM area uptake [15].
PK11195 binding potential (BPND) maps were gener-
ated at a voxel level using the simplified reference tissue
model [22] implemented in MATLAB. As all anatomical
regions in the brain can contain voxels with specific
PK11195 binding in Alzheimer’s disease, a Supervised
Cluster Analysis (SVCA) with 6 classes [23] that was ap-
plied to the dynamic images to localise clusters of voxels
which either contained specific tissue binding or which
provided a reference tissue input function representing
normal GM uptake kinetics. Signal from voxels with the
kinetics of vascular endothelial uptake was discarded.
The PK11195 images were spatially normalized into
MNI space in the same manner as described for the PiB
images. PK11195 images were smoothed with a 6-mm
FWHM Gaussian filter prior to parametric analysis, see
also [15].
Cortical surface mapping
Vector based cortical surface statistical mapping was
used to localise subject and mean group significant dif-
ferences in tracer uptake over time and correlations be-
tween levels of tracer binding. Cortical surfaces were
generated with FACE (fast accurate cortex extraction)
[24, 25]. In FACE, topologically correct surface meshes
are iteratively fitted to the WM-GM and the GM-CSF
interface with sub-voxel precision using pre-processed
T1 weighted images [26]. FACE has been shown to be
robust, accurate and fast [27].
Cortical surfaces were transformed into PET native
space using the transformation matrix from a rigid body
co-registration between PET and T1 weighted images
[20]. PET parameters were interpolated and mapped to
the surface approximating the middle cortical layer in
order to minimize the influence of partial volume effects.
Individual surfaces were registered to the cortical surface
of an average non-linear anatomical template in MNI
space [28] using a feature driven surface registration al-
gorithm [29]. Parameter values were then mapped to the
average surface and smoothed using a 20-mm FWHM
geodesic Gaussian kernel. Smoothing along the cortical
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surface eliminates the unwanted blurring across gyri
caused by smoothing in voxel space.
Statistical analyses
STATA 14.2 (stataCorp LP, TX, USA) and Prism 8
(GraphPad Software. La Jolla, CA, USA) were used for
statistical analyses. Differences in non-imaging variables
between the high and low PiB groups were assessed
using the general linear model, while a Wilcoxon rank-
sum test was used to interrogate skewed variables. P
values < 0.01 were considered statistically significant to
correct for multiple comparisons when interrogating
non-imaging parameters. The subjects’ demographics
and cognitive status are summarised descriptively in
Table 1.
Cortical surface statistical maps of mean differences in
tracer binding parameters were calculated at each sur-
face vertex using a vertex specific general linear model
implemented in Python. Cortical areas showing correla-
tions between binding parameters were interrogated
using the general linear model. All statistical maps were
initially thresholded at P = 0.05 to visually localise areas
of potential significant change. These areas then had a
family wise error (FWE) rate correction applied using
the cluster-extent-based thresholding software and a pri-
mary cluster-defining threshold of p < 0.05. The cluster-
extent threshold was calculated using Gaussian random
field implemented in SPM12 using the estimated
intrinsic smoothness based on residual maps [30]. The
Visbrain software was used to visualize cortical surface
maps (https://www.frontiersin.org/articles/10.3389/
fninf.2019.00014/full).
Determining Aβ status
Our MCI cohort showed a bimodal distribution, with a
clear separation of high and low PiB uptake clusters at a
baseline composite cortical:cerebellar PiB SUVR of 1.5 [31].
Results
Characteristics of the studied populations
The characteristics of our study population are summa-
rized in Table 1.
The baseline MCI cohort comprised 43 cases (mean
age 70 years; range 50–83) which had both PiB and
PK11195 PET and a subgroup of 25 subjects who also
had flortaucipir PET. Twenty-seven (63%) of the 43 MCI
cases had a composite cortical PiB SUVR > 1.5 at base-
line and were categorized as high PiB representing pro-
dromal Alzheimer’s disease. Thirteen of these 27 high
PiB cases had follow-up PET with all three tracers.
The follow-up cohort comprised of thirty-eight of the
MCI cases which had longitudinal PET with PiB and
PK11195, and 22 of these cases had additional longitu-
dinal PET with flortaucipir.
The high and the low PiB uptake MCI groups were simi-
lar with regard to gender, years of education and follow-up
time. The baseline high PiB MCI cases showed a signifi-
cantly higher prevalence of ApoE4 carriage than the low
PiB MCI cases (64.3% v 18.8%; p = 0.009), a lower baseline
MoCA score and a greater cognitive decline—see Table 1.
Changes in binding of the three radiotracers from
baseline to 2-year follow-up in the high- and low-PiB MCI
groups
All cortical surface statistical mapping results were de-
termined using an uncorrected threshold of P < 0.05 to
initially localise areas of potential significant change
followed by an FWE rate correction of P < 0.05 applied
to clusters to confirm the presence of significant change.
The longitudinal changes in PiB, PK11195 and flortauci-
pir levels are presented for the baseline high PiB MCI
group in Fig. 1a. This prodromal AD cohort showed
areas of significantly increased cortical PiB SUVR and
flortaucipir levels at a 2-year follow-up compared with
baseline while the level and extent of the PK11195 signal
had decreased. The cortical increase in PiB SUVR levels
after 2 years was widespread, while flortaucipir increases
were seen in discreet areas of frontal, temporal and
parietal lobes. Cortical PK11195 binding decreases were
bilateral with a fronto-temporal emphasis.
Our low baseline PiB MCI group showed no signifi-
cant flortaucipir signal at baseline—see Fig. 1b in
[16]. The longitudinal changes in PiB and PK11195
for the entire low PiB group of 15 MCI cases are pre-
sented in Fig. 1b. Small areas of significant increase
in PiB uptake were seen reflecting the contribution of
seven subjects who individually showed a rise in their
cortical PiB uptake over the 2-year interval, three
reaching the 1.5 SUVR threshold. We have previously
reported this significant difference in baseline levels
of brain inflammation between the high and the low
PiB MCI cohorts [15].
Table 1 Demographic and cognitive data
High PiB group Low PiB group P value
Baseline (n) 27 16
Female, % 32.1 % 50% 0.29
Age (years) 73 ± 6.0 66 ± 8.6 0.0025
Education 12.5 ± 2.9 12.2 ± 3.4 0.74
Follow-up (months)a 24.3 ± 1.2 24.9 ± 2.6 0.32
ApoE4 64.3% (n = 26) 18.8% (n = 15) 0.009
MoCA
Baseline 23.4 ± 3.3 25.7 ± 2.8 (n = 15) 0.025
Follow-up 21.4 ± 4.9 25.2 ± 3.4 0.005
aBetween PiB scan dates. Data presented as mean ± sd. n number, MoCA
montreal cognitive assessment
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Correlations of PiB and PK11195 in the low-PiB MCI group
Fifteen of our MCI cases were categorised as low/normal
PiB at baseline and showed cortical surface areas where
PiB uptake and levels of PK11195 uptake were positively
correlated at baseline and again 2 years later. The cor-
tical areas of positive correlation between PiB and
PK11195 uptake became more extensive at the 2-year
follow-up compared to the baseline findings, Fig. 2a. In
this low-PiB MCI group, 7 of the 15 subjects showed in-
creasing cortical PiB SUVR values at a 2-year follow-up,
and three SUVRs now exceeding the 1.5 threshold for
raised amyloid and so had formally converted to pAD
Fig. 1 Cortical surface maps of mean tracer uptake and changes. a Cortical surface maps of mean PiB (upper), PK (middle) and flortaucipir (lower
row) uptake for the high PiB MCI subjects at baseline and after 2 years follow-up. On the right, results of a paired t test between baseline and
follow-up show increased amyloid in all cortical association areas, increased tau in frontal and occipital cortical areas, and reduced inflammation
in fronto-temporal cortical regions after 2 years. b Mean PiB (upper) and PK (lower) uptake for the low PiB subjects at baseline and after 2 years
follow-up. The results of a paired t test show small areas of increased amyloid, but no changes in inflammation levels over 2 years (P < 0.05;
cluster FWE rate, P < 0.05)
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[31]. When examining the positive correlation between
PiB and PK11195 uptake in those 7 subjects with rising
PiB uptake (Fig. 2b), we found a similar pattern of posi-
tive correlation as for the entire group of 15 low PiB
subjects. In contrast, the 8 subjects who had stable low
PiB SUVR values over 2 years showed no significant
areas of positive correlation between PiB and PK11195
uptake (Fig. 2c). These findings implied the low-PiB
MCI group consisted of two separate populations: a
group of seven early prodromal Alzheimer cases missed
by applying a conventional 1.5 SUVR PiB threshold for
prodromal AD and a group of eight subjects who did
not have AD.
Correlations between cortical uptake in the high PiB MCI
group, at baseline and 2-year follow-up
Correlations of cortical PiB and PK11195 uptake in the high
PiB group
At baseline, scattered areas where cortical levels of PiB
and PK11195 binding were positively correlated and were
detected in frontal and parietal lobes across the high PiB
group of 27 MCI (prodromal AD) subjects (Fig. 3a). Two
years later, the returning 23 high PiB MCI subjects
showed that the positively correlated PiB and PK11195
signals now had extended to involve the occipital cortex
(Fig. 3a). No negative correlations between PiB and
PK11195 levels were seen. However, the influence of tau
load on the apparent correlation between cortical β-
amyloid and inflammation levels still needed to be
assessed. When we covaried out the effect of tau load
(flortaucipir binding) on the association between PiB and
PK11195 uptake levels in the 22 subjects who also had
flortaucipir scans, the positive correlation between PiB
and PK11195 uptake levels no longer remained
statistically significant—see Fig. 3b. This implied that in-
flammation due to tau tangle formation could be influen-
cing the apparent correlation between PiB and PK11195
levels in our high-PiB MCI cohort—see below.
Correlations between flortaucipir and PK11195 in the high
PiB MCI group
Directly interrogating the association between flortauci-
pir and PK11195 levels, we found a positive correlation
between levels of flortaucipir and PK11195 uptake in
areas of cortex at both baseline and at a 2-year follow-
up in the 13 high PiB MCI subjects who had all three
PET tracers—see Fig. 4a. Flortaucipir and PK11195
levels were positively correlated in these cortical areas
before and after covarying out the variance in PK11195
uptake associated with Aβ deposition (PiB binding).
While the locations of cortical areas showing signifi-
cantly correlated levels of flortaucipir and PK11195 up-
take remained unchanged after covarying out amyloid
effects, the extent of the correlations were smaller (Fig.
4b). This finding confirms that in high-PiB MCI, it is tau
tangles that have the major influence on levels of
inflammation.
The effect of PK11195 on the correlation between PiB and
flortaucipir at baseline and follow-up
When interrogating the association between PiB and
flortaucipir levels across 13 high PiB subjects, we found
cortical areas of positive correlation between PiB and
flortaucipir binding both at baseline and more so after 2
years of follow-up (Fig. 5a). The areas of correlation
remained similar after correcting for any effect of in-
flammation (Fig. 5b). This suggests that inflammation
Fig. 2 Amyloid and inflammation correlations in the low PiB group. Regions where uptake of PiB and PK are positively correlated in the low PiB
group at baseline and after 2 years. a Across the 15 low PiB MCI subjects. b Baseline and follow-up correlation for the 7 low PiB subjects who
showed increasing PiB signal over 2 years—three crossing the 1.5 threshold. c Baseline and follow-up correlation for 8 cases in the low PiB
subgroup who showed no increase in PiB uptake over 2 years (P < 0.05; cluster FWE rate, P < 0.05)
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does not act as the link between levels of amyloid and
tau deposition.
Discussion
Our longitudinal PET study was designed to investigate
in vivo the spatial and temporal relationships between
levels of neuroinflammation and the load of cortical Aβ
and tau tangles at baseline and 2-year time points in
MCI subjects. In this report, we have used a vector-
based approach (FACE) to localise significant inter-
correlations between the different imaging markers of
Alzheimer’s pathology on the cortical surface. Our longi-
tudinal data show that (#1) levels of cortical inflamma-
tion declined in temporal and frontal areas over 2 years
in pAD cases (MCI cases with high PiB uptake at base-
line) although their Aβ and tau loads were still rising
(Fig. 1). Cross-sectional findings from other groups have
also suggested a decline in inflammation levels as pAD
Fig. 3 Amyloid and inflammation level correlation maps. Regions where levels of PiB and PK uptake were positively correlated a across high PiB
MCI subject at baseline and after 2 years of follow-up. b Baseline and follow-up correlations after correction for tau influence across 22 subjects
who had all three tracers. P < 0.05; cluster FWE rate, P < 0.05. Tau load influences the correlation between amyloid and inflammation levels
Fig. 4 Tau and inflammation correlation maps in 13 high PiB MCIs. Positive correlation between flortaucipir and PK uptake. a Baseline and follow-
up correlation in 13 high PiB MCI subjects. b baseline and follow-up correlation after correction for amyloid influence (P < 0.05; cluster FWE rate,
P < 0.05). Amyloid load did not influence the correlation between tau and inflammation levels
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progresses to clinical AD, the earliest pAD cases show-
ing the highest inflammation levels [13, 32].
In our baseline low PiB MCI group, 7 cases showed a
rise in Aβ load over 2 years (three into the Alzheimer
range) and had levels of cortical inflammation that cor-
related with PiB uptake. This suggests that these low PiB
MCI cases may initially have had early Thal phase 1 or 2
levels of Aβ present below our 1.5 SUVR threshold of
abnormality and progressed over the 2 years associated
with increased levels of inflammation—see Fig. 3 [31, 33,
34]. The 8 low PiB MCI cases which remained stable
over 2 years showed no association between levels of PiB
and PK11195 uptake and are unlikely to have Alzhei-
mer’s disease.
Using voxel-based biological parametric mapping
(BPM), we previously reported clusters of significant
correlation between Aβ load and inflammation in MCI
at baseline [15] but found no significant association be-
tween tau load and inflammation levels [16]. In this
present study, we used FACE, a more sensitive vector-
based cortical surface mapping approach to localise cor-
tical surface areas where MCI cases with high PiB at
baseline, and MCI cases with low PiB which rose after 2
years and had significant positive correlations between
their Aβ load and inflammation levels—Figs. 2 and 3
[24]. While we were able to localise cortical areas where
Aβ load and inflammation levels were positively corre-
lated, in the high-PiB MCI group when we covaried out
the effect of tau deposition on inflammation, the correl-
ation between Aβ and inflammation levels was no longer
statistically significant (Fig. 3). This suggests that it was
the concomitant effect of the tau present on
inflammation levels that was responsible for the appar-
ent correlation between Aβ and inflammation levels in
prodromal AD with an amyloid load approaching Alz-
heimer levels. This would not be surprising as Aβ levels
plateau in Alzheimer’s disease and are approaching a
steady level in the high PiB MCI group making correla-
tions with inflammation difficult to demonstrate,
whereas tau levels still continue to rise in these subjects.
(#2) Our findings support the view that inflammation
can be present in the earliest prodromal Alzheimer dis-
ease stages as our 7 baseline low PiB MCI cases who
showed rising PiB uptake over 2 years had correlated
levels of Aβ and inflammation—Fig. 2. It has been re-
ported that cortical Aβ needs to be present before tau
tangles form [9]. Those of our baseline low PiB MCI
group who had flortaucipir PET showed no evidence of
tau tangle deposition [16] so tau is unlikely to be a con-
founder that could explain the correlated amyloid load
and inflammation levels in these low PiB MCI cases.
(#3) In Alzheimer brain slices, activated microglia are
seen surrounding both Aβ plaques and dying neurones
containing tau tangles [1]. Post-mortem studies have
also shown a positive correlation between activated
microglia and NFT densities [2]. Our current findings
support an association of tau tangles with raised inflam-
mation levels in later prodromal stages of the disease—
that is high PiB MCI cases— confirmed by our finding
of a positive correlation between tau tangle load and in-
flammation levels across cortical areas at the 2-year
follow-up. This correlation between tau and inflamma-
tion levels survived removal of the variance due to Aβ
load on inflammation levels with ANCOVA even after
Fig. 5 Tau and amyloid correlation maps in 13 high PiB subjects. a Positive correlation between PiB and flortaucipir levels in 13 high PiB subjects
at baseline and after 2 years of follow-up. b The above correlation after correction for inflammation (P < 0.05; cluster FWE rate, P < 0.05).
Inflammation did not influence the correlation between tau and amyloid levels
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applying an FWE correction to the cortical signals
(Fig. 4). Comparing the localizations of cortical areas
where PiB and PK11195 uptake were correlated with
those where flortaucipir and PK11195 uptake were
correlated, there was considerable overlap in their lo-
cation, and these areas of correlation increased in ex-
tent over 2 years as the disease progressed.
The extended amyloid cascade hypothesis suggests
that amyloid deposition leads to tau tangle formation
with inflammation being a possible intermediate medi-
ator of this chain. We have interrogated with ANCOVA
the influence of inflammation levels on the positive cor-
relation seen between amyloid and tau levels in our high
PiB MCI cases (Fig. 5). We found that inflammation
levels had no influence on the significance of the associ-
ation between amyloid and tau loads. This is against in-
flammation driving tau tangle formation after Aβ
deposition has occurred. We also explored the effect of
Aβ levels on the correlation between tau and inflamma-
tion levels in our high PiB MCI cases and found no in-
fluence. In contrast, tau had a significant influence on
the association between Aβ and inflammation levels in
high-PiB MCI. Overall, our findings suggest that inflam-
mation is more likely to be a direct response to Aβ and
tau deposition than a cause of either of these abnormal
protein aggregations.
The finding of inflammation in early MCI cases has
been suggested to play a protective role by removing
Aβ fibrils. If so, stimulation of microglial activation
could possibly be advocated as a protective strategy in
early prodromal AD cases, perhaps even before clin-
ical symptoms occur. Immunotherapy would be a rea-
sonable approach for achieving this in early disease
stages.
Later in prodromal and early Alzheimer’s disease, the
activated microglia fail to clear Aβ plaques and decline
in number. In established Alzheimer’s disease, cortical fi-
brillar Aβ load reaches a plateau, and at this time, tau
tangle load starts to rise facilitated by the presence of Aβ
plaques in some manner that remains unclear. There is
then a second wave of inflammatory activity in MCI
which we and others have shown correlates with tau tan-
gle levels [13]. It is proposed that these microglia have a
neurotoxic phenotype and a microglial suppressant to
reduce cytokine levels could be a rational protective
intervention.
Limitations of this study
This is a single centre study with a relatively low number
of cases compared to multicentre series such as ADNI.
We used a first generation TSPO PET tracer, 11C-
PK11195, to detect inflammation, which has a higher
background signal than second generation ligands but
has the advantage that its binding is not influenced by
the TSPO polymorphisms expressed by subjects. Specific
PK11195 uptake was modelled by extracting a tissue
non-specific reference cluster of voxels representing the
kinetics of normal cortical grey matter but this reference
cluster can contain voxels with low levels of specific
binding occasionally leading to cortical voxels with ap-
parent negative binding. 11C-PK11195 PET is strictly a
marker of translocator protein (TSPO) expression and
not microglial density. Elevations in TSPO are a non-
specific reaction to inflammation, and TSPO is also
expressed by cells other than microglia, including acti-
vated astrocytes [35]. One, therefore, has to be cautious
in interpreting TSPO rises as entirely due to inflamma-
tion. TSPO is also expressed by vascular endothelia and
the choroid plexus. The SVCA modelling approach we
used filters out the kinetic components of tracer uptake
by endothelial and choroidal epithelium cells though it
cannot separate activated astrocyte and microglial sig-
nals. Post-mortem studies [35, 36] suggest, however, that
the major TSPO signal comes from microglia in Alzhei-
mer’s disease, but we acknowledge that some of the sig-
nal may also reflect activation of astrocytes. It seems
reasonable to consider TSPO signal as a marker of in-
trinsic neuroinflammation.
We used 18F-Flortaucipir PET as our marker of paired
helical tau but this modality shows off-target binding to
iron rich proteins and melanin primarily seen subcorti-
cally [37].
Conclusions
In summary, we have investigated at baseline and at a 2-
year follow-up the relationship between inflammation
levels and the loads of Aβ and tau across a group of
MCI cases, the majority of whom had prodromal Alzhei-
mer’s disease. Using an improved vector-based approach
for localising significant changes in tracer uptake at cor-
tical surfaces, we have found that (a) levels of inflamma-
tion decline in prodromal AD cases. (b) In MCI cases
with low/normal cortical PiB uptake who subsequently
show increased amyloid deposition over 2 years, levels of
inflammation correlate with their Aβ load. (c) Con-
versely, MCI cases which had a high Aβ load ap-
proaching Alzheimer levels at baseline on their PiB PET,
overall levels of inflammation declined over 2 years.
Additionally, there was an association between tau ra-
ther than amyloid load and levels of inflammation in
these subjects. These findings are compatible with a
two-peak hypothesis of inflammatory activity in Alzhei-
mer’s disease, and the first peak being driven by amyloid
aggregation and possibly having a protective role and
the second being driven by tau tangle formation and be-
ing neurotoxic (a). This suggests that one cannot simply
boost or suppress inflammation as a protective strategy
in Alzheimer’s disease—a rational treatment approach to
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stimulating or suppressing inflammation that will de-
pend on whether brain regions in each subject are in the
earliest phase of AD where microglia may be protective
or in a later phase of the disease where they may have a
neurotoxic phenotype.
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